nach oben

Annals of Hematology

Erschienen in:

29.10.2018 | Original Article

Prognostic significance of monocyte chemoattractant protein-1 and CC chemokine receptor 2 in diffuse large B cell lymphoma

verfasst von: Yan-Li Li, Zhi-Hu Shi, Xian Wang, Kang-Sheng Gu, Zhi-min Zhai

Erschienen in: Annals of Hematology | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Aberrant monocyte chemoattractant protein-1 (MCP-1) and CC chemokine receptor 2 (CCR2) expression in malignant tissues have been reported; however, their role in hematological malignancies prognosis remains little known. The aim of this study was to investigate the prognostic value of MCP-1 and CCR2 expression in patients with diffuse large B cell lymphoma (DLBCL). The study included 221 patients with DLBCL. MCP-1 and CCR2 expression was analyzed by immunohistochemical staining and its correlations with clinicopathologic features and prognosis were evaluated. High expression of MCP-1 or CCR2 was correlated with clinicopathological characteristics, and an adverse prognostic factor for overall survival (OS) and progression-free survival (PFS) of DLBCL patients. Also, significant positive correlation between MCP-1 and CCR2 expression was revealed (r = 0.545, P < 0.001). Patients with high MCP-1 or high CCR2 expression had significantly poorer OS and PFS than those with low MCP-1 or low CCR2 expression (OS: P < 0.001, P < 0.001; PFS: P < 0.001, P < 0.001), respectively, even in the rituximab era, and MCP-1 or CCR2 expression could further identify high-risk patients otherwise classified as low/intermediate risk by the International Prognostic Index (IPI) alone. Furthermore, incorporation of MCP-1 or CCR2 expression into the IPI score could improve prognostic value for OS. This is the first report describing the clinicopathological features and survival outcome according to expression of MCP-1 and CCR2 in DLBCL.

Nur mit Berechtigung zugänglich

Habermann TM (2012) New developments in the management of diffuse large B-cell lymphoma. Hematology 17:S93–S97CrossRefPubMed

Friedberg JW (2011) Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program 2011:498–505CrossRefPubMed

Hiratsuka S, Watanabe A, Aburatani H, Maru Y (2006) Tumor-mediated up-regulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 8(12):1369–1375CrossRefPubMed

Allavena P, Germano G, Marchesi F, Mantovani A (2011) Chemokines in cancer related inflammation. Exp Cell Res 317:664–673CrossRefPubMed

Matsushima K, Larsen CG, DuBois GC, Oppenheim JJ (1989) Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. J Exp Med 169(4):1485–1490CrossRefPubMed

Monti P, Leone BE, Marchesi F, Balzano G, Zerbi A, Scaltrini F, Pasquali C, Calori G, Pessi F, Sperti C, Di Carlo V, Allavena P, Piemonti L (2003) The CC chemokine MCP-1/CCL2 in pancreatic cancer progression: regulation of expression and potential mechanisms of antimalignant activity. Cancer Res 63(21):7451–7461PubMed

Lu Y, Cai Z, Galson DL, Xiao G, Liu Y, George DE, Melhem MF, Yao Z, Zhang J (2006) Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate 66(12):1311–1318CrossRefPubMed

Dwyer RM, Potter-Beirne SM, Harrington KA, Lowery AJ, Hennessy E, Murphy JM, Barry FP, O’Brien T, Kerin MJ (2007) Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells. Clin Cancer Res 13(17):5020–5027CrossRefPubMed

Zhang XW, Qin X, Qin CY, Yin YL, Chen Y, Zhu HL (2013) Expression of monocyte chemoattractant protein-1 and CC chemokine receptor 2 in non-small cell lung cancer and its significance. Cancer Immunol Immunother 62(3):563–570CrossRefPubMed

10.

Li X, Yao W, Yuan Y, Chen P, Li B, Li J, Chu R, Song H, Xie D, Jiang X, Wang H (2017) Targeting of tumor-infiltrating macrophages via CCL2/CCR2signalling as a therapeutic strategy against hepatocellular carcinoma. Gut 66(1):157–167CrossRefPubMed

11.

Tao LL, Shi SJ, Chen LB, Huang GC (2014) Expression of monocyte chemotactic protein-1/CCL2 in gastric cancer and its relationship with tumor hypoxia. World J Gastroenterol 20(15):4421–4427CrossRefPubMedPubMedCentral

12.

Wang Z, Xie H, Zhou L, Liu Z, Fu H, Zhu Y, Xu L, Xu J (2016) CCL2/CCR2 axis is associated with postoperative survival and recurrence of patients with non-metastatic clear-cell renal cell carcinoma. Oncotarget 7(32):51525–51534PubMedPubMedCentral

13.

Salcedo R, Ponce ML, Young HA, Wasserman K, Ward JM, Kleinman HK, Oppenheim JJ, Murphy WJ (2000) Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 96(1):34–40PubMed

14.

Brummer G, Acevedo DS, Hu Q, Portsche M, Fang WB, Yao M, Zinda B, Myers M, Alvarez N, Fields P, Hong Y, Behbod F, Cheng N (2018) Chemokine signaling facilitates early-stage breast Cancer survival and invasion through fibroblast-dependent mechanisms. Mol Cancer Res 16(2):296–308CrossRefPubMed

15.

Macanas-Pirard P, Quezada T, Navarrete L, Broekhuizen R, Leisewitz A, Nervi B, Ramírez PA (2017) The CCL2/CCR2 axis affects transmigration and proliferation but not resistance to chemotherapy of acute myeloid leukemia cells. PLoS One 12(1):e0168888CrossRefPubMedPubMedCentral

16.

Fang WB, Jokar I, Zou A, Lambert D, Dendukuri P, Cheng N (2012) CCL2/CCR2 chemokine signaling coordinates survival and motility of breast cancer cells through Smad3 protein- and p42/44 mitogen-activated protein kinase (MAPK)-dependent mechanisms. J Biol Chem 287:36593–36608CrossRefPubMedPubMedCentral

17.

Izhak L, Wildbaum G, Jung S, Stein A, Shaked Y, Karin N (2012) Dissecting the autocrine and paracrine roles of the CCR2-CCL2 axis in tumor survival and angiogenesis. PLoS One 7(1):e28305CrossRefPubMedPubMedCentral

18.

Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, Kaiser EA, Snyder LA, Pollard JW (2011) CCL2 recruits inflammatory monocytes to facilitate breast tumor metastasis. Nature 475(7355):222–225CrossRefPubMedPubMedCentral

19.

van Deventer HW, Palmieri DA, Wu QP, McCook EC, Serody JS (2013) Circulating fibrocytes prepare the lung for cancer metastasis by recruiting Ly6C+ monocytes via CCL2. J Immunol 190(9):4861–4867CrossRefPubMed

20.

Zhao L, Lim SY, Gordon-Weeks AN, Tapmeier TT, Im JH, Cao Y, Beech J, Allen D, Smart S, Muschel RJ (2013) Recruitment of a myeloid cell subset (CD11b/Gr1mid) via CCL2/CCR2 promotes the development of colorectal cancer liver metastasis. Hepatology 57(2):829–839CrossRefPubMed

21.

Yang J, Lv X, Chen J, Xie C, Xia W, Jiang C, Zeng T, Ye Y, Ke L, Yu Y, Liang H, Guan XY, Guo X, Xiang Y (2016) CCL2-CCR2 axis promotes metastasis of nasopharyngeal carcinoma by activating ERK1/2-MMP2/9 pathway. Oncotarget 7(13):15632–15647PubMed

22.

Izumi K, Fang LY, Mizokami A, Namiki M, Li L, Lin WJ, Chang C (2013) Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation. EMBO Mol Med 5(9):1383–1401CrossRefPubMedPubMedCentral

23.

Yao W, Ba Q, Li X, Li H, Zhang S, Yuan Y, Wang F, Duan X, Li J, Zhang W, Wang H (2017) A natural CCR2 antagonist relieves tumor-associated macrophage-mediated immunosuppression to produce a therapeutic effect for liver cancer. Ebio-Medicine 22:58–67

24.

Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, ThieleJ VJW (2008) World Health Organization classification of tumors of Haematopoietic and lymphoid tissues. IARC, Lyon

25.

(1993) A predictive model for aggressive NHL: The International non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329(14): 987–994

26.

Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang W, Xiong YQ, Wu WZ, Wang L, Tang ZY, Sun HC (2008) High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol 26(16):2707–2716CrossRefPubMed

27.

Pitkin L, Luangdilok S, Corbishley C, Wilson PO, Dalton P, Bray D, Mady S, Williamson P, Odutoye T, Rhys Evans P, Syrigos KN, Nutting CM, Barbachano Y, Eccles S, Harrington KJ (2007) Expression of CC chemokine receptor 7 in tonsillar cancer predicts cervical nodal metastasis, systemic relapse and survival. Br J Cancer 97(5):670–677CrossRefPubMedPubMedCentral

28.

Li YL, Pan YY, Jiao Y, Ning J, Fan YG, Zhai ZM (2014) Peripheral blood lymphocyte/monocyte ratio predicts outcome for patients with diffuse large B cell lymphoma after standard first-line regimens. Ann Hematol 93(4):617–626CrossRefPubMed

29.

Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059–3068CrossRefPubMedPubMedCentral

30.

Charo IF, Ransohoff RM (2006) The many roles of chemokines and chemokine receptors in inflammation. New Engl J Med 354(6):610–621CrossRefPubMed

31.

Koide N, Nishio A, Sato T, Sugiyama A, Miyagawa S (2004) Signficance of macrophage chemoattractant protein-1 expression and macrophage infiltration in squamous cell carcinoma of the esophagus. Am J Gastrogenterol 99(9):1667–1674CrossRef

32.

Vande Broek I, Leleu X, Schots R, Facon T, Vanderkerken K, Van Camp B, Van Riet I (2006) Clinical signficance of chemokinereceptor (CCR1, CCR2 and CXCR4) expression in human myeloma cells: the association with disease activity and survival. Haematologica 91(2):200–206PubMed

33.

Lu Y, Cai Z, Xiao G, Liu Y, Keller ET, Yao Z, Zhang J (2007) CCR2 expression correlates with prostate cancer progression. J Cell Biochem 101(3):676–685CrossRefPubMed

34.

Wyler L, Napoli CU, Ingold B, Sulser T, Heikenwälder M, Schraml P, Moch H (2014) Brain metastasis in renal cancer patients: metastatic pattern, tumor-associated macrophages and chemokine/chemoreceptor expression. Br J Cancer 110(3):686–694CrossRefPubMed

35.

Rothe C, Urlinger S, Löhning C, Prassler J, Stark Y, Jäger U, Hubner B, Bardroff M, Pradel I, Boss M, Bittlingmaier R, Bataa T, Frisch C, Brocks B, Honegger A, Urban M (2008) The human combinatorial antibody library HuCAL GOLD combines diversification of all six CDRs according to the natural immune system with a novel display method for efficient selection of high-affinity antibodies. J Mol Biol 376(4):1182–1200CrossRefPubMed

36.

Xue CB, Wang A, Meloni D, Zhang K, Kong L, Feng H, Glenn J, Huang T, Zhang Y, Cao G, Anand R, Zheng C, Xia M, Han Q, Robinson DJ, Storace L, Shao L, Li M, Brodmerkel CM, Covington M, Scherle P, Diamond S, Yeleswaram S, Vaddi K, Newton R, Hollis G, Friedman S, Metcalf B (2010) Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2. Bioorg Med Chem Lett 20(24):7473–7478CrossRefPubMed

37.

Loberg RD, Ying C, Craig M, Yan L, Snyder LA, Pienta KJ (2007) Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res 67(19):9417–9424CrossRefPubMed

38.

Moisan F, Francisco EB, Brozovic A, Duran GE, Wang YC, Chaturvedi S, Seetharam S, Snyder LA, Doshi P, Sikic BI (2014) Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers. Mol Oncol 8(7):1231–1239CrossRefPubMedPubMedCentral

39.

Mitchem JB, Brennan DJ, Knolhoff BL, Belt BA, Zhu Y, Sanford DE, Belaygorod L, Carpenter D, Collins L, Piwnica-Worms D, Hewitt S, Udupi GM, Gallagher WM, Wegner C, West BL, Wang-Gillam A, Goedegebuure P, Linehan DC, DeNardo DG (2012) Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res 73(3):1128–1141CrossRefPubMedPubMedCentral

40.

Maxwell PJ, Neisen J, Messenger J, Waugh DJ (2014) Tumor-derived CXCL8 signaling augments stroma-derived CCL2-promoted proliferation and CXCL12-mediated invasion of PTEN-deficient prostate cancer cells. Oncotarget 5(13):4895–4908CrossRefPubMedPubMedCentral

41.

Sanford DE, Belt BA, Panni RZ, Mayer A, Deshpande AD, Carpenter D, Mitchem JB, Plambeck-Suess SM, Worley LA, Goetz BD, Wang-Gillam A, Eberlein TJ, Denardo DG, Goedegebuure SP, Linehan DC (2013) Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis. Clin Cancer Res 19(13):3404–3415CrossRefPubMedPubMedCentral

42.

Pham LV, Pogue E, Ford RJ (2018) The role of macrophage/B-cell interactions in the pathophysiology of B-cell lymphomas. Front Oncol 8:147CrossRefPubMedPubMedCentral

Titel: Prognostic significance of monocyte chemoattractant protein-1 and CC chemokine receptor 2 in diffuse large B cell lymphoma
verfasst von: Yan-Li Li
Zhi-Hu Shi
Xian Wang
Kang-Sheng Gu
Zhi-min Zhai
Publikationsdatum: 29.10.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Annals of Hematology / Ausgabe 2/2019
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-018-3522-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2019

Clinical impact of prognostic nutritional index in diffuse large B cell lymphoma

Epidemiological, clinical and genetic characterization of aplastic anemia patients in Pakistan

Treating early-stage myelofibrosis

Utility of allogeneic hematopoietic stem cell transplantation using international donors in a homogenous ethnic population: question in the era of various alternative donors

Low extracellular vesicle–associated tissue factor activity in patients with persistent lupus anticoagulant and a history of thrombosis